Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Achieve Life Sciences to post earnings of ($0.29) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Achieve Life Sciences Trading Up 2.2 %
Shares of Achieve Life Sciences stock traded up $0.06 during mid-day trading on Friday, hitting $2.81. 207,633 shares of the stock were exchanged, compared to its average volume of 170,817. The stock has a market capitalization of $97.46 million, a price-to-earnings ratio of -2.49 and a beta of 1.67. Achieve Life Sciences has a twelve month low of $2.51 and a twelve month high of $5.59. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The company has a 50-day simple moving average of $3.09 and a 200 day simple moving average of $3.95.
Insider Transactions at Achieve Life Sciences
In related news, CFO Mark K. Oki acquired 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $28,900. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.00% of the company's stock.
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Recommended Stories
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
